Fig. 10
From: Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker
Correlations of RNF43 expression with TMB, MSI, and the immunotherapy efficacy. A, B Correlations between RNF43 expression and tumor mutation burden (TMB) and microsatellite instability (MSI) in pan-cancer. C–E Relationship between RNF43 expression and response to immunotherapy in three cohorts, C IMvigor, D GSE67501, and E GSE78220 *p < 0.05, p < 0.01, ***p < 0.001